Non-small-cell lung cancer

Nature Reviews Disease Primers, Journal Year: 2024, Volume and Issue: 10(1)

Published: Sept. 26, 2024

Language: Английский

---

Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up

Journal of Thoracic Oncology, Journal Year: 2024, Volume and Issue: 19(8), P. 1228 - 1241

Published: April 18, 2024

Language: Английский

---

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

European Journal of Cancer, Journal Year: 2024, Volume and Issue: 211, P. 114296 - 114296

Published: Aug. 25, 2024

We report 5-year efficacy and safety outcomes from CheckMate 9LA in patients with metastatic non-small cell lung cancer (mNSCLC) exploratory analyses key patient subgroups.

Language: Английский

---

Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab–ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial

The Lancet Respiratory Medicine, Journal Year: 2024, Volume and Issue: 12(11), P. 877 - 887

Published: Aug. 16, 2024

Language: Английский

---

Efficacy and safety of nivolumab and ipilimumab with or without chemotherapy for unresectable non-small cell lung cancer: a multicenter retrospective observational study

Cancer Immunology Immunotherapy, Journal Year: 2025, Volume and Issue: 74(2)

Published: Jan. 3, 2025

Language: Английский

---

Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions

Nature Reviews Clinical Oncology, Journal Year: 2025, Volume and Issue: 22(3), P. 200 - 214

Published: Jan. 6, 2025

Language: Английский

---

Non–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations

American Society of Clinical Oncology Educational Book, Journal Year: 2024, Volume and Issue: 44(3)

Published: April 26, 2024

This overview provides a thorough review of current treatment approaches for first-line management nononcogenic addicted non–small cell lung cancer. We also address pertinent clinical decision-making queries encountered in everyday practice, such as the optimal strategy PD-L1–high patients, predictive factors response to immune checkpoint inhibitors (ICI) both terms patient and cancer characteristics, potential benefits dual blockade, unresolved issue safe discontinuation strategies long-term responders. Around one five patients falls into this latter category while majority develop either primary or acquired resistance ICI-based therapy, necessitating effective subsequent lines treatment. Docetaxel, with without combination antiangiogenic agents, serves backbone treatment, although evidence post-ICI setting is limited. Given that an inflamed tumor microenvironment (TME) crucial ICI responses, targeting TME cases alongside continued administration appears rational, trials so far have failed confirm hypothesis. Antibody-drug conjugates emerged promising modality, offering reduced toxicity improved efficacy by specific antigens. Moreover, several chemotherapy-free are currently under investigation treatment-naïve including alternative drugs epitopes on cells.

Language: Английский

---

Evolving Precision First-Line Systemic Treatment for Patients with Unresectable Non-Small Cell Lung Cancer

Cancers, Journal Year: 2024, Volume and Issue: 16(13), P. 2350 - 2350

Published: June 26, 2024

First-line systemic therapy for patients with advanced or metastatic non-small cell lung cancer (NSCLC) has rapidly evolved over the past two decades. First, molecularly targeted a growing number of

Language: Английский

---

Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment—Comparison with Stage III Disease

Cancers, Journal Year: 2024, Volume and Issue: 16(6), P. 1174 - 1174

Published: March 17, 2024

Background: In patients with oligometastatic NSCLC, a cT3–cT4 primary tumor or an cN2/cN3 lymph node status was reported to be associated unfavorable outcome. The aim of this study assess the importance definitive neoadjuvant thoracic radiochemotherapy for long-term outcome these in order find more appropriate treatment schedules. Methods: Analysis West Cancer Centre (WTZ) institutional database from 08/2016 08/2020 performed. Patients synchronous OMD, all without actionable driver mutations, who received (RCT) RCT followed by surgery (trimodality treatment) were included. Survival is compared stage III NSCLC. Results: Altogether, 272 concurrent radiochemotherapy. Of those, 220 presented (158 RCT, 62 trimodality approach). A total 52 had OMD cT3/cT4 tumors. Overall survival (OS) at five years 28.3% (95%-CI: 16.4–41.5%), which not significantly different OS NSCLC treated (34.9% 27.4–42.8%)). However, PFS last follow-up worse than that (13.0% vs. 24.3%, p = 0.0048). latter due higher cumulative incidence distant metastases (50.2% 20.4% 48 months, < 0.0001) comparison patients. cross-validated classifier included severe comorbidity, ECOG performance status, gender and pre-treatment serum CRP level as most important factors univariable analysis, able divide patient group into two equally sized groups four-year rate 49.4% good prognosis 9.9% poor (p 0.0021). Laboratory chemistry clinical parameters, addition imaging high-precision therapies, can help predict improve prognosis. Conclusions: multimodality approach local metastases-directed therapy chemoimmunotherapy lead comorbidities therefore recommended.

Language: Английский

---

A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 6, 2025

PD-1/PD-L1 inhibitors are novel immunotherapeutic agents that have been approved for first-line treatment in advanced non-small cell lung cancer (NSCLC). This study aims to evaluate the efficacy and safety of inhibitors, which completed phase 3 clinical trials, as a patients with NSCLC. A systematic search PubMed, Embase Cochrane Library was performed extract eligible literature up October 2023. Findings included overall survival (OS), objective response rate (ORR), progression-free (PFS), grade ≥3 treatment-related adverse events (TRAEs). Furthermore, subgroup analyses were conducted based on PD-L1 expression levels histological type. We analyzed 29 studies including 18,885 patients. In all patients, penpulimab plus chemotherapy led way OS (HR 0.55, 95% CI: 0.40-0.75) PFS 0.43, 0.27-0.67). Regarding OS, ≥50%, 1%-49% <1%, camrelizumab + 0.48, 0.21-1.11), cemiplimab 0.50, 0.32-0.79) nivolumab ipilimumab 0.64, 0.51-0.81) considered optimal treatments. Compared chemotherapy, monotherapy nivolumab, cemiplimab, pembrolizumab, atezolizumab durvalumab had lower odds TRAE ≥3. most effective therapy, but preferences varied by expression, histology type associated outcomes. Safety at individual patient level must be high priority decision-making process. Further validation is warranted.

Language: Английский

---